Based on the findings from the examination of 133 patients with stable angina pectoris, it was shown that He-Ne laser therapy with the irradiation being applied to the liver projection area in combination with the prolonged-action nitrates is superior to similar application of irradiation to the precordial region and Head's zones or intravenous irradiation of blood. Revealed in the examination of the above patients was a reaction of antiproteolytic enzymes to He-Ne laser therapy, which appeared to be varying with methods of laser therapy. It is suggested that a reaction of the realization of the components of proteolysis might be involved in the realization of therapeutic effect of the He-Ne laser energy in patients with ischemic heart disease.
To assess left ventricular systolic and diastolic function, M-mode (n = 675) and transmitral Doppler echocardiography (n = 358) were performed in patients with stable angina pectoris and compared with 50 matched healthy controls. Left ventricular fractional shortening (FS) was significantly lower in male than in female patients (32 +/- 7 vs. 35 +/- 7%, p
Days of high ambient carbon dioxide (CO) have been associated with increased hospital admissions for cardiac disease. This study was conducted to determine if daily concentrations of CO and fine particulates (PM2.5) are associated with daily changes in heart rate variability.
Each of 36 adults with coronary artery disease had personal exposure to PM2.5 and CO measured along with heart rate variability for one 24-hour period each week for up to 10 weeks.
Among those not taking beta-receptor blockers, there was a positive association between the standard deviation of the R-to-R intervals and CO (P = 0.02). No effect was found for PM2.5.
Urban exposure to CO may exert a biologic effect on the heart, which may be modified by medications.
The object of this investigation was to describe the choice of recommended/non-recommended anti-anginal preparations in a group of patients in a hospital and prescribed by the general practitioner on discharge and during the subsequent three years. Eighty-nine patients participated in the investigation. Sixty-nine of these received medicinal treatment at the conclusion of the period. The investigation demonstrates that the recommendations by the Danish Drug Committee were followed in 90% of the cases during the last year of observation. It is concluded that the activities of the Danish Drug Committee may influence the choice of anti-anginal preparations on discharge from hospital and during the subsequent three years.
In a double-blind, randomized, placebo-controlled study comparing verapamil and placebo in late secondary intervention after acute myocardial infarction, the physicians were asked to try to identify the treatment in 100 consecutive patients. The assessment of the presumed treatment was based upon the presence of effects and side effects. It was only possible correctly to group 36% (95%: 26.7-46.2) of the patients. 35 patients were grouped as indeterminable. In 65 a treatment was proposed, correctly in 55%, and thus ideal blindedness had been achieved.
Ranolazine is a new compound that has been approved by the FDA for use in patients who have chronic stable angina refractory to conventional antianginal medications. Ranolazine proved to be effective also as monotherapy in patients with stable angina and as part of a combination regimen. This review is inspired by the presentation that legendary figures in contemporary cardiology, such as Braunwald, Komajda and Camm made recently at the Congress of the European Society of Cardiology held in Stockholm, Sweden, last September.
126 patients with chronic exercise-induced angina, who were accustomed to the use of sublingual glyceryl trinitrate, were entered into a multicentre 2-week crossover comparison of sublingual (Nitromex) and buccal (Suscard) formulations of glyceryl trinitrate. Before randomisation the patients underwent a training period when doses of the buccal formulation were individualised. There were 31% fewer attacks with the buccal formulation, and more patients reported higher physical activity on the buccal compared with the sublingual formulation (30% vs 16%). The buccal formulation was also more effective when glyceryl trinitrate was used prophylactically to prevent expected attacks, being effective in 74% of attempts compared with 66% for the sublingual formulation (p less than 0.05). More patients preferred the buccal route of administration for prophylactic use (81% vs 4%, p less than 0.05). Similarly, when asked to select which they would use in future, 65% of patients preferred the buccal formulations (p less than 0.05), 19% preferred sublingual glyceryl trinitrate, and 16% did not express any preference.
To study patient selection for and persistence with ADP receptor-inhibiting oral antiplatelet (OAP) treatment after acute coronary syndrome (ACS).
Observational, retrospective, cohort study linking real-life patient-level register data.
Nationwide drug usage study using data of patients with ACS discharged from hospitals in Finland.
The study population consisted of 54 416 patients (aged =18 years) following hospital admission for unstable angina pectoris or myocardial infarction during 2009-2013. Patients were classified as either OAP or non-OAP users based on drug purchases within 7 days of discharge.
Initiation of and a 12-month persistence with OAP medication.
In total, 49% of patients with ACS received OAP treatment after hospital discharge. Women represented 40% of the population, but only 32% of them became OAP users (adjusted OR for initiation compared with men 0.8; p38% and p20 percentage points for each).
Only half of the patients with ACS received guideline-recommended ADP receptor-inhibiting OAP treatment after hospital discharge, suggesting suboptimal treatment practices. Non-PCI-treated patients and patients with increased age, unstable angina, dementia or atrial fibrillation appear to have the highest risk of deficient treatment with OAPs. OAP users, however, showed good compliance during drug usage.
Cites: Am J Epidemiol. 2004 Jun 1;159(11):1040-615155288
Cites: Eur Heart J. 2014 Dec 7;35(46):3267-7625265973